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Mineralocorticoid Receptor Antagonism Attenuates
Vascular Apoptosis and Injury via Rescuing
Protein Kinase B Activation
Yongzhong Wei, Adam T. Whaley-Connell, Javad Habibi, Jenna Rehmer, Nathan Rehmer,
Kamlesh Patel, Melvin Hayden, Vincent DeMarco, Carlos M. Ferrario,
Jamal A. Ibdah, James R. Sowers
Abstract—Emerging evidence indicates that mineralocorticoid receptor (MR) blockade reduces the risk of cardiovascular
events beyond those predicted by its blood pressure–lowering actions; however, the underlying mechanisms remain
unclear. To investigate whether protection elicited by MR blockade is through attenuation of vascular apoptosis and
injury, independently of blood pressure lowering, we administered a low dose of the MR antagonist spironolactone or
vehicle for 21 days to hypertensive transgenic Ren2 rats with elevated plasma aldosterone levels. Although Ren2 rats
developed higher systolic blood pressures compared with Sprague-Dawley littermates, low-dose spironolactone
treatment did not reduce systolic blood pressure compared with untreated Ren2 rats. Ren2 rats exhibited vascular injury
as evidenced by increased apoptosis, hemidesmosome-like structure loss, mitochondrial abnormalities, and lipid
accumulation compared with Sprague-Dawley rats, and these abnormalities were attenuated by MR antagonism. Protein
kinase B activation is critical to vascular homeostasis via regulation of cell survival and expression of apoptotic genes.
Protein kinase B serine473 phosphorylation was impaired in Ren2 aortas and restored with MR antagonism. In vivo MR
antagonist treatment promoted antiapoptotic effects by increasing phosphorylation of BAD serine136 and expression of
Bcl-2 and Bcl-xL, decreasing cytochrome c release and BAD expression, and suppressing caspase-3 activation.
Furthermore, MR antagonism substantially reduced the elevated NADPH oxidase activity and lipid peroxidation,
expression of angiotensin II, angiotensin type 1 receptor, and MR in Ren2 vasculature. These results demonstrate that
MR antagonism protects the vasculature from aldosterone-induced vascular apoptosis and structural injury via rescuing
protein kinase B activation, independent of blood pressure effects. (Hypertension. 2009;53:158-165.)
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Clinical studies indicate that mineralocorticoid receptor(MR) blockade exerts beneficial effects on cardiovascu-
lar events beyond those predicted by its blood pressure
(BP)–lowering actions.1–4 Experimental evidence further sug-
gests that aldosterone exerts direct adverse effects on the
vasculature, contributing to vascular injury and remodel-
ing.5–8 However, the underlying molecular mechanisms by
which signaling through the MR elicits these deleterious
vascular effects independently of BP increases remain to be
elucidated.
Apoptosis has been implicated in the pathogenesis of
vascular injury and remodeling, leading to development of
vascular disease.9–11 Excessive apoptosis contributes to vas-
cular cell loss, impairs endothelium-dependent vasorelax-
ation, promotes inflammation, and enhances procoagulant
activity.12 Evidence indicates that increased hemodynamic
and mechanical forces contribute to vascular cell apoptosis.13
Aldosterone further promotes apoptosis in cultured endothe-
lial cells (ECs),14 implying a direct or indirect role in the
pathogenesis of vascular apoptosis and injury. The extent to
which the vascular protective effects of MR blockade in vivo
are the direct result of attenuation of apoptosis independent of
BP reductions, and the molecular mechanisms involved in
this protective effect, remains unclear.
Protein kinase B (Akt), a serine (Ser)/threonine protein
kinase, plays a critical role in inhibiting cardiovascular cell
apoptosis, including ECs.15 Akt Ser473 residue phosphoryla-
tion exerts antiapoptotic actions through several mechanisms,
including regulation of mitochondrial membrane integrity,
suppression of proapoptotic signaling, and enhancement of
antiapoptotic molecule expression. BAD, a proapoptotic mol-
ecule, initiates apoptosis by binding to the antiapoptotic
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molecules Bcl-xL and Bcl-2 on the outer mitochondrial mem-
brane, causing cytochorome c release into the cytosol.16–18 Akt
phosphorylates BAD on Ser136, which prevents BAD from
binding to Bcl-xL and Bcl-2, thus preventing the proapoptotic
function of BAD.16 Akt also plays an important role in cell
metabolism and regulation of various vascular functions. Indeed,
Akt knockout mice exhibit various vascular abnormalities,
including increased apoptosis and lipid accumulation.19
It was reported recently that in vitro aldosterone treatment
impairs Akt activation in vascular smooth muscle cells
(SMCs).20 Accordingly, we hypothesized that aldosterone,
acting through MR stimulation, suppresses vascular Akt
activation, which, in turn, promotes vascular apoptosis and
lipid accumulation and injury. We further hypothesized that
the effects of aldosterone could be attenuated by in vivo
treatment with the MR antagonist spironolactone. To this end,
we used the transgenic Ren2 rat model, which overexpresses
the mouse renin gene in the adrenal glomerulosa, resulting in
elevated aldosterone plasma levels.21,22 Furthermore, to as-
sess BP-independent effects of MR antagonism on the vas-
culature protection, we used a dose of spironolactone, which
does not reduce systolic BP (SBP) in hypertensive Ren2 rats.23
Materials and Methods
Details of the materials and methods can be found in an online
supplement available at http://www.hypertension.aha.org.
Animals and Treatments
Animal procedures were followed by the University of Missouri
Animal Care and Use Committee and National Institutes of Health
guidelines. Six- to 7-week-old male transgenic heterozygous (/)
Ren2 rats and Sprague-Dawley (SD) littermates were assigned
randomly to SD vehicle–treated, Ren2 vehicle–treated controls
(Ren2-C) and Ren2 spironolactone groups (6 to 7 rats per group).
Rats were implanted with a subcutaneous time-release, matrix-driven
delivery pellet containing either spironolactone (5 mg; 0.24 mg/day)
or vehicle for 21 days.23
Systolic BP
SBP was measured before and after treatment.23
Aorta Dissection and Protein Extraction
Thoracic aorta was used in this study.
NADPH Oxidase Activity Assay
NADPH oxidase activity was measured as described previously.24
Western Blot Analysis
4-Hydroxy-nonenal (4-HNE), 3-nitrotyrosin, cytochrome c, BAD,
BAD Ser136, total-Akt, Akt Ser473 phosphorylation, caspase-3, and
angiotensin type 1 receptor (AT1R) were analyzed by Western blot.
Immunofluorescence
Paraffin and cryostat sections were used for immunohistochemistry
with the following antibodies against: BAD Ser136, Bcl-2, Bcl-xL,
Akt Ser473, Akt threonine308, angiotensin II (Ang II), AT1R, MR,
Nox2, Rac1, p67phox, or 3-nitrotyrosine, respectively.
Evaluation of Apoptotic Cell Death by TUNEL
TUNEL assay was performed using In Situ Cell Death Detection Kit
(Roche Diagnostics).
Oil Red O Staining
Oil Red O staining was performed on frozen aortic sections.
Transmission Electronic Microscopy
The ultrastructural changes of vasculature were examined by trans-
mission electronic microscopy (TEM).
Statistical Analysis
All data are reported as the meansSEM. Dunnett’s test or Student
t test was used to determine the significance among groups. A value
of P0.05 was considered statistically significant.
Results
Spironolactone Treatment Did not Influence SBPs
in Ren2 Rats
Ren2 rats at 6 to 7 weeks of age had higher SBP than SD
controls (SD-C; P0.01), which increased further at 9 to 10
weeks of age (P0.01). Spironolactone treatment did not
reduce SBP compared with untreated Ren2 rats (P0.05;
Figure 1A). Interestingly, despite not reducing SBP, spirono-
lactone treatment attenuated the increases in medial wall
thickness observed in untreated Ren2 rats (Figure 1B).
Spironolactone Treatment Attenuated Vascular
Activity of Renin-Angiotensin-Aldosterone System
in Ren2 Rats
To determine whether spironolactone treatment affects aortic
tissue renin-angiotensin-aldosterone system activity, expres-
sion of MR, Ang II, and AT1R was analyzed using immuno-
histochemistry and Western blot. Ren2 aortas exhibited
increased MR expression (Figure 1C), Ang II (Figure 1D and
1E) and AT1R (Figure 1F and 1G) compared with SD, all
attenuated with spironolactone treatment.
Spironolactone Treatment Attenuated Vascular
Oxidative Stress in Ren2 Rats
Lipid peroxidation was determined by measuring 4-HNE and
3-nitrotyrosine by Western blot (Figure 2A and 2B) and
immunohistochemistry (data not shown). There was a signif-
icant increase of 4-HNE (Figure 2A) and 3-nitrotyrosine
(Figure 2B) in Ren2 aortic tissues compared with SD, and
spironolactone treatment decreased 4-HNE and
3-nitrotyrosine levels in Ren2 aortas (Figure 2A and 2B). To
determine whether attenuation of lipid peroxidation by spi-
ronolactone treatment in Ren2 aortas is attributable to sup-
pression of NADPH oxidase activation, the activity and
subunit expression of this enzyme were measured. Ren2
aortas exhibited greater activity (Figure 2C) and increased
expression of Nox2, Rac1, and p67phox subunits (Figure 2D,
2E, and 2F, respectively) of NADPH oxidase compared with
SD, attenuated with spironolactone treatment compared with
untreated Ren2-C (Figure 2C through 2F).
Spironolactone Treatment Improved Vascular Akt
Activation in Ren2 Rats
Akt Ser473 phosphorylation was significantly decreased in
Ren2 aortas compared with SD (P0.05), which was im-
proved with spironolactone treatment compared with un-
treated Ren2 aortas (P0.05; Figure 3A). Immunostaining
intensities for Akt Ser473 and theorine308 were decreased in
Ren2 aortic sections compared with SD and similarly im-
proved with spironolactone treatment (Figure 3B and 3C).
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Spironolactone Treatment Enhanced BAD Ser136
Phosphorylation and Antiapoptotic Protein
Expression in Ren2 Rats
Expression of BAD Ser136 phosphorylation (Figure 4A and
4B), Bcl-2 (Figure 4C), and Bcl-xL (Figure 4D) was de-
creased in Ren2 aortas compared with SD and improved with
spironolactone treatment compared with untreated Ren2 aor-
tas (Figure 4A through 4D). In contrast, BAD expression was
significantly increased in Ren2 aortas compared with SD, and
attenuated with spironolactone treatment (Figure 4E).
Spironolactone Treatment Attenuated Vascular
Mitochondrial Abnormalities and Cytochrome c
Release in Ren2 Rats
Mitochondrial damage impairs mitochondrial membrane in-
tegrity and causes cytochrome c release into cytosol, contrib-
uting to apoptosis.17,18,25 Mitochondria are vulnerable to
damage by a variety of pathological insults, including reac-
tive oxygen species.26 Ultrastructural analysis demonstrated
that Ren2 vascular mitochondria displayed abnormalities,
including swelling, cristae disruption, and reduced matrix
density compared with SD vasculature, and these abnormal-
ities were partly corrected after spironolactone treatment
(Figure 5A). Double immunostaining for mitochondrial com-
plex 4 subunit 1 and cytochrome c showed that there was a
diffuse staining pattern for cytochrome c, which did not
colocalize with mitochondrial complex 4 subunit 1 staining in
Ren2 aortas compared with SD (Figure 5B). These alterations
in cytochrome c staining in Ren2 aortic tissue were partly
corrected with spironolactone treatment (Figure 5B). Western
blot analysis showed that there was increased cytochrome c
release into cytosol in Ren2 aortic tissues compared with SD,
which was attenuated with spironolactone treatment (Figure 5C).
Spironolactone Treatment Attenuated Vascular
Apoptosis in Ren2 Rats
TEM ultrastructural analysis demonstrated apoptotic cells
with nuclear condensation, clumping, and loss of cytosolic
and plasma membrane integrity in ECs and SMCs in Ren2
arteries (Figure 6A). TUNEL staining showed that there were
apoptotic ECs and SMCs in Ren2 aortic sections (Figure 6B).
As shown in Figure 6C, there was 2.6-fold increase of
apoptotic cells in Ren2 aortic sections compared with SD
(P0.01), which was substantially reduced after spironolac-
tone treatment (P0.05). Immunoblot analysis further con-
firmed this observation that Ren2 vasculatures exhibited
increased activated caspase-3, a key enzyme in apoptosis
pathways, compared with SD-C (P0.05), which were atten-
uated after spironolactone treatment (P0.05) (Figure 6D).
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ity in Ren2 rats. A, SBP was measured at the initial and final stages of experiment. B, Average aortic media thickness. C, Average gray
scale intensities of immunostaining for MR. D, Representative immunostaining images for Ang II (ANG II). E, Average gray scale intensi-
ties of immunostaining for Ang II. F, Representative immunostaining images for AT1R. G, Representative Western blot for AT1R (top; 50
kDa); bar graph showed the band densitometry analysis (bottom). The results are meansSEM from 6 to 7 rats per group. **P0.01 vs
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Spironolactone Treatment Attenuated Vascular
Ultrastructural Abnormalities in Ren2 Rats
Evidence suggests that activated caspase-3 cleaves inte-
grin 4, a key component of hemidesmosomes, promoting
apoptosis.27 TEM showed that Ren2 vasculatures exhibited
hemidesmosome-like structure (endothelial basal adhesion
plaque) loss, which was attenuated with spironolactone
treatment (Figure 7A). The basal adhesion plaques that
promote adhesion of the endothelium to the internal elastic
matrix were structurally similar to hemidesmosomes re-
sponsible for epithelial cell–matrix attachments, and they
are thus referred to as hemidesmosome-like structures.
Hemidesmosome-like structure loss disrupts cell–matrix
(elastin of the internal elastic lamina) interaction and
adhesion, which might have contributed to increased
vascular EC apoptosis observed in Ren2 vasculatures. A
recent study suggests that aldosterone stimulates migration
of vascular SMCs.28 Ren2 vasculatures also displayed
SMC migration into intimal layer and internal elastic lamina
disruption compared with SD vasculatures and were attenuated with
spironolactone treatment (data not shown).
Spironolactone Treatment Attenuated Vascular
Lipid Accumulation in Ren2
Lipid accumulation in vasculature is also a characteristic of
vascular injury/maladaptation.29,30 Impaired Akt activation and
damaged mitochondria have been suggested to promote vascular
lipid accumulation.19 Oil red O staining indicated increased lipid
accumulation in media (Figure 7B) and ECs (data not shown) in
Ren2 aortas compared with SD; this observation was supported
by TEM (Figure 7C). Lipid accumulation in Ren2 aortas was
attenuated with spironolactone treatment (Figure 7B and 7C).
Discussion
Evidence suggests that MR blockade exerts a protective
effects on cardiovascular outcomes.1–3 Although increased
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BP mediated by aldosterone causes vascular injury, recent
evidence suggests that aldosterone also exerts direct maladap-
tive effects on the vasculature.5,7,31 Although vascular injury
is a key step for initiation and progression of cardiovascular
diseases, little is known regarding the molecular mechanisms
underlying aldosterone-induced deleterious effects on the
vasculature. The current investigation provides novel findings
that MR blockade delivers a direct protection against aldo-
sterone-induced vascular apoptosis, mitochondrial damage,
lipid accumulation, and endothelial basal hemidesmosome-
like structure loss via rescuing Akt activation, independent of
BP/hemodynamic actions.
The transgenic Ren2 rat overexpresses the mouse renin
gene in the adrenal glomerulosa, resulting in increased tissue
Ang II and elevated plasma aldosterone levels. We observed
previously that AT1R blockade32 and treatment with high
doses of spironolactone (our unpublished observation, 2007)
significantly decrease BP in Ren2 rats, suggesting that Ang II
and aldosterone are involved in hypertension development in
Ren2 rats. We report here that Ren2 aortas exhibit increased
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aortic tissue levels of Ang II, AT1R, and MR compared with
SD. In the present investigation, we used a very low dose of
spironolactone to determine whether MR blockade provides
direct vasculature protection independent of BP reduction.
The measurement of BP by the tail-cuff method may be a
limitation in the current study; nevertheless, low-dose spi-
ronolactone treatment reduced aortic tissue levels of Ang II,
AT1R, and MR in Ren2 rats. This is consistent with a recent
report that spironolactone in higher doses (50 mg/kg per day)
reduces the expression of angiotensin converting enzyme,
MR, and aldosterone synthase in streptozotocin-induced dia-
betic kidney.33 Our data suggest that MR blockade exerts
direct protection from vascular injury, in part, through mod-
ulation of Ang II, AT1R, and MR expression in the Ren2 rat
model.
Apoptosis has been implicated as an important mechanism in
the pathogenesis of vascular disease.11,34 Apoptosis promotes
vascular cell loss. Apoptosis also induces vascular dysfunction,
inflammatory cell infiltration, and lipid accumulation, all of
which further aggravate vascular cell apoptosis.11,12 There were
significantly increased apoptotic endothelial and SMC deaths
detected by TUNEL assay in Ren2 aortas compared with SD
aortas, and these differences were substantially decreased
after spironolactone treatment (Figure 4). TUNEL assay is a
sensitive and standard technique for studying apoptosis in
various tissues. However, TUNEL assay may also recognize
cells undergoing DNA repair.35,36 We further corroborated
our TUNEL results with morphological characterization of
apoptosis by light microscope and TEM as well as DNA
electrophoresis. Both light microscopic (data not shown) and
TEM findings (Figure 4) indicated that there were more
apoptotic nuclei in Ren2 aortic sections compared with SD,
and this difference was attenuated with spironolactone treat-
ment (data not shown). Furthermore, DNA electrophoresis
showed that there were increased DNA fragmentations in
Ren2 aortic tissue compared with SD, attenuated with spi-
ronolactone treatment (data not shown). In addition, active
caspase-3, a more specific indicator for cells going to apo-
ptosis, was increased in Ren2 aortic tissues compared with
SD, abrogated after spironolactone treatment (Figure 4).
Collectively, these novel data support the notion that MR
antagonism exerts a direct protective role in vascular tissue
exposed to high levels of circulating aldosterone. Our results
are consistent with recent reports that aldosterone induces cell
apoptosis in cultured ECs,14 proximal tubular cells,37 mesan-
gial cells,38 and cardiac myocytes.39 In contrast, a recent
report indicates that spironolactone induces cell apoptosis in
cultured mononuclear cells.40 Together, these data suggest
that the effects of spironolactone on cell apoptosis may be
dependent on the cell type and culture conditions. We extend
these in vitro observations and report here for the first time
that in vivo MR antagonism attenuates vascular cell apoptosis
independent of BP-lowering action.
Our findings also suggest that the vasculature protections
by MR blockade are mediated by suppression of oxidative
stress and improvement of Akt activation. In this regard, Akt
Ser473 phosphorylation/activation was dramatically decreased
in Ren2 aortas and was substantially improved after spirono-
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lactone treatment (Figure 3). Interestingly, immunostaining
intensities of Akt Ser473 phosphorylation on ECs were
comparable among SD-C, Ren2-C, and Ren2 spironolac-
tone (data not shown); although immunostaining intensi-
ties of Akt threonine308 phosphorylation in ECs were
dramatically decreased in Ren2 aortic sections compared
with SD, they were increased with spironolactone treat-
ment (data not shown). Our results are consistent with a
recent report that aldosterone impairs Akt activation in
cultured vascular SMCs.20 The increased levels of 4-HNE
and 3-nitrotyrosine in Ren2 aortas were markedly de-
creased with spironolactone treatment (Figure 2). The
increased activity and expression of NADPH oxidase ob-
served in Ren2 aortas were abrogated after spironolactone
treatment, suggesting that there is MR mediation of NADPH
oxidase activation as a source of oxidative stress. Oxidative
stress has been shown to inhibit Akt activation in various tissues,
including vasculature through direct or indirect actions.41
Akt activation is crucial in cell survival17–19,25 through
inhibiting apoptosis by suppressing proapoptotic or enhanc-
ing antiapoptotic signal, as well as regulation of mitochon-
drial membrane integrity and cytochrome c release. BAD is a
proapoptotic molecule and usually maintained in phosphory-
lated and sequestered form in the cytosol. When dephosphor-
ylated, BAD migrates into mitochondria, binds to Bcl-2 and
Bcl-xL, and releases cytochrome c into the cytosol. Akt
activation promotes phosphorylation and inactivation of
BAD.17,18 Akt activation increases antiapoptotic molecule
expression such as Bcl-2.17,18 Akt phosphorylation also pro-
motes Akt translocation to the nucleus, where it affects the
transcription of target genes and exerts protective activity.42
Indeed, decreased expression of BAD Ser136 phosphoryla-
tion, Bcl-xL, and Bcl-2 was observed in Ren2 aortas com-
pared with SD and was improved after spironolactone treat-
ment. This was consistent with attenuation of mitochondrial
injury and cytochrome c release into cytosol in treated Ren2
vasculatures with spironolactone. Our results are also consis-
tent with a recent study that aldosterone treatment enhances
dephosphorylation of phosphor–BAD and release of cyto-
chrome c into cytosol in cultured mesangial cell.38 Increased
cytochrome c in cytosol activates caspase-3, resulting in cell
apoptosis. Active caspase-3 has been shown recently to
cleave the key component integrin 4 of hemidesmosomes
and impair hemidesmosome formation, promoting apopto-
sis.27 Ren2 arteries exhibited hemidesmosome-like structural
loss, which was preserved by spironolactone treatment; these,
together with increased proapoptotic proteins, contribute to
increased vascular apoptosis and injury in Ren2 rats.
Akt activation also plays a vital role in regulating cell
metabolism, including lipid oxidation. Lipid accumulation is
a prominent feature of vascular disease and also an etiologic
factor of vascular injury. Indeed, Akt knockout mice display
increased vascular lipid accumulation and develop severe
vascular injury and atherosclerosis.19 In this context, there
was increased vascular lipid accumulation in Ren2 aortas,
abolished by in vivo MR blockade.
In summary, the results of this investigation indicate that
elevated aldosterone levels acting via the MR promote
NADPH oxidase activation/reactive oxygen species produc-
tion, which, in turn, impairs Akt activation and consequently
causes activation of apoptotic signaling pathways, lead to
vascular cell apoptosis, lipid accumulation, and injury.
Perspectives
This investigation provides novel evidence that MR antago-
nism provides direct protection of vascular cells from apo-
ptosis and injury independent of BP/hemodynamic actions.
These protective effects are mediated by improvement of Akt
activation and suppression of cell death pathways. These data
also demonstrate that there is a potentially distinct therapeutic
target mediated via rescuing Akt activation. Finally, these
data help us understand some of the molecular mechanisms
by which therapy with MR antagonists have provided pro-
tection against cardiovascular events in patients at high risk.
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Expanded Materials and Methods 
Animals and treatments  
Animal procedures were followed by the University of Missouri Animal Care and Use 
Committee and NIH guidelines. Male transgenic heterozygous (+/-) Ren2 rats and Sprague-
Dawley (SD) littermates were received at 5-6 wk of age from Bowman Gray School of 
Medicine, Wake Forest University, Winston-Salem, NC.  After arrival, the animals were allowed 
1 week to become acclimatized to the environment, and they had free access to standard chow 
and tap water. The rats were randomly assigned to SD vehicle-treated (SD-C), Ren2 vehicle-
treated (Ren2-C) and Ren2 spironolactone (Ren2-Sp) groups (6-7 rats/group). Rats were 
implanted with a subcutaneous time-release, matrix-driven delivery pellet (Innovative Research 
of America, Sarasota, FL) containing either spironolactone (5 mg; 0.24 mg/d) or vehicle for 21 
day.1 
Systolic Blood Pressure 
Systolic blood pressure (SBP) was measured in triplicate using the tail-cuff method 
(Harvard Systems, Student Oscillometric Recorder) prior to and after treatment.1 
Materials 
Anti-4-Hydroxy-2-Nonenal (4-HNE) antibody was obtained from OXIS International 
Inc. (Portland, OR) and Alpha Diagnostic International (San Antonio, TX).  Antibodies against 
BAD, BAD Ser136, Bcl-2, and Bcl-xL were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA) and the antibodies against Akt, Akt Ser473, Akt Thr308, cytochrome c, and caspase-3 
were obtained from Cell Signaling Technology (Beverly, MA). Antibodies against angiotensin II 
(ANG II), angiotensin type 1 receptor (AT1R), mineralocorticoid receptor (MR), Nox2, Rac1, 
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p67phox, or 3- nitrotyrosine, were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) 
and Cell Signaling Technology (Beverly, MA). In Situ Cell Death Detection Kit was purchased 
from Roche Applied Science (Indianapolis, IN). 
Aorta Dissection and Protein Extraction  
Aorta from arch to diaphragm was carefully dissected from the animals. The thoracic 
aorta was used in this investigation. The arch and top 1/3 of the thoracic aorta was removed. A 2 
mm section of the aortic fragment was then removed for histological analysis and 
immunohistochemistry. Another 2 mm section was removed for either TEM analysis or Oil Red 
O staining. The remaining thoracic aorta was combined with the previously removed arch and 
top section of the aorta for tissue homogenization and various assay analysis. Aortic samples 
were homogenized in ice-cold homogenization buffer (20 mM HEPES, 10 mM KCl, 1.5 mM 
MgCl2, 1 mM EGTA, 1mM EDTA, 1 mM DTT, 250 mM sucrose, 0.1 mM PMSF, 2 µM 
leupeptin, 2 µM pepstatin A, pH 7.4) 2 mg/ml pepstatin, leupeptin, and aprotinin) using a Duall 
homogenizer.  A portion of the whole homogenate (WH) was saved. Remaining WH was 
centrifuged at 800g for 10 min at 4C to remove nuclei and cell debris. The resulting supernatant 
(S1) was further centrifuged at 13,000g for 20 min at 4C two times, with the resulting 
supernatant (S2) and pellet containing mitochondria. 
NADPH Oxidase Activity Assay 
NADPH oxidase activity was measured as previously described.2  Briefly, the S2 fraction 
(50 µg protein) from above was incubated with NADPH (100 µM) at 37o C and the rate of 
NADPH consumption monitored by measuring the decline in absorbance (340 nm) every 10 min, 
using a plate reader spectrophotometer (Bio-Tek EL808).  
Western Blot Analysis 
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To determine levels of lipid peroxidation in aortas, 4-HNE and 3-nitrotyrosine were 
evaluated by immunoblot. 4-HNE is a highly toxic by-product of lipid peroxidation and a 
sensitive marker of oxidative stress.  An aliquot of S1 fractions (20 µg protein), as described 
above, was separated using 10% SDS-PAGE, transferred to nitrocellulose or PVDF membrane, 
and incubated with primary anti-4-HNE antibody (1:1000) or anti-3-nitrotyrosine (1:1000), 
washed, and incubated with an HRP-conjugated secondary antibody (1:10000). The signaling 
was captured using phosphor-imager (Bio-RAD). The intensities of the bands were quantified 
using Quantity One software.  
To detect cytochrome c release, the mitochondria-free cytosolic fractions (S2) were 
prepared as above. S2 fractions containing 15 µg proteins were loaded in 12% SDS-PAGE, 
transferred to PVDF, probed with an anti-cytochrome c antibody (1:1000), and followed by an  
HRP-conjugated secondary antibody (1:10000). The intensities of the bands were quantified as 
described above. 
To determine expression of BAD, BAD Ser136, Akt, Akt Ser473, caspase-3, or AT1R, 
twenty µg aliquots of the S2 fractions prepared as above were separated by 10% SDS-PAGE 
gels, transferred to PVDF, and probed with primary antibodies (1:1000), respectively.  The 
intensities of the bands were quantified as described above.   
Immunofluorescence 
Immunohistochemical staining was performed on paraffin or cryostat sections (5µm) of 
aortic tissue. Sections were incubated with the following antibodies: anti-BAD Ser136 (1:200), 
Bcl-2 (1:400), Bcl-xL (1:400), Akt Ser473 (1:200), Akt Thr308 (1:200), angiotensin II (ANG II) 
(1:200), angiotensin type 1 receptor (AT1R) (1:200), mineralocorticoid receptor (MR) (1:200), 
Nox2 (1:400), Rac1 (1:400), p67phox (1;400), or 3-nitrotyrosine (1:400), respectively.  After 
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washing, slides were incubated with secondary antibodies conjugated with Alex 488 or 568 or 
647. Images were acquired using a Laser-Scanning confocal microscopy (Olympus IX70) and 
gray scale intensities were measured.  
Evaluation of Apoptotic Cell Death by TUNEL 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay 
was performed using In Situ Cell Death Detection Kit per manufacturer’s instructions (Roche 
Diagnostics, Indianapolis, IN). TUNEL-positive and -negative cells were counted in 5 random 
fields from 5 rats/each group. Results are expressed as number of TUNEL-positive cell/total cells 
x 100%.  
Oil Red O Staining  
To determine the presence of lipid accumulation in the vasculature, Oil Red O staining 
was performed on frozen aortic sections. Frozen sections (5 µm) were fixed in 10% neutral 
buffer formalin for 10 min. after washing with distilled water; the sections were stained with Oil 
Red O for 15 min. The images were acquired with the Laser-Scanning confocal microscope 
(Olympus IX70). 
Transmission Electronic Microscopy 
Transmission electron microscope (TEM) was used to examine the ultrastructural 
changes associated vascular injury and remodeling. Aortic samples were collected and fixed in 
2% glutaraldehyde/2% paraformaldehyde, and secondary fixation with 1% osmium tetroxide, 
embedded in Epon-Spurr’s resin, sectioned at 85nm, and stained with uranyl acetate/Sato’s triple 
lead stain. Electron microscopy was performed at University of Missouri-Columbia Electron 
Microscopy Core Facility using JEOL 1200-EX TEM.   
Statistical Analysis 
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All data are reported as the means ± SEM. Dunnett’s test or Student’s t-test were used to 
determine the significance among groups. A value of P<0.05 was considered to be statistically 
significant.   
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